Although multiple mechanisms underlying aberrant AR-dependent transcription have been clearly established at the molecular level, current therapeutic modalities lack the power to permanently disrupt aberrant AR activity in prostate tumor cells. This evidence concerns the gene AR and prostate neoplasm.